Urinary excretion of interferon, albumin, and beta 2-microglobulin during interferon treatment.
Serum and urinary levels of albumin, beta 2-microglobulin, and interferon were determined in ten patients undergoing interferon therapy. The pharmacokinetics during a phase I trial of interferon administration intramuscularly is presented. Only trace amounts of interferon activity are found in the urine, even during peak serum interferon activity. Serum beta 2-microglobulin levels increased after interferon treatment, especially at the higher dosing levels. Urinary excretion of beta 2-microglobulin increased due to the relatively low affinity of the transport system. Saturation, competition, or inhibition of the absorption process for beta 2-microglobulin was not attained. Measurement of the urinary albumin/urinary beta 2-microglobulin ratio reveals no glomerular or tubular lesion, and we conclude that interferon therapy does not result in a clinically significant nephrotoxicity.
D000328:Adult; D000368:Aged; D000419:Albuminuria; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use / Q000652:urine*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy* / Q000652:urine; D001613:beta 2-Microglobulin / Q000652:urine*
D007370:Interferon Type I; D001613:beta 2-Microglobulin